Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study

You-Jung Choi,Jaehyun Lim,Sungho Bea,Jieun Lee,Jah Yeon Choi,Seung Young Rho,Dae-In Lee,Jin Oh Na,Hyung-Kwan Kim

DOI: https://doi.org/10.1093/eurheartj/ehae335

IF: 39.3

2024-07-13

European Heart Journal

Abstract:Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0–21 days following COVID-19 vaccination. The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77–1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39–2.54) following vaccination. In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination. Summary of the study population, methods, and main findings. AF, atrial fibrillation; AFL, atrial flutter; K-COV-N, Korea Disease Control and Prevention Agency–COVID-19–National Health Insurance Service; CI, confidence interval; COVID-19, coronavirus disease 2019; IRR, incidence rate ratio

cardiac & cardiovascular systems